Clinical trials: IOL
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
This phase II trial studies how well giving lenalidomide with or without rituximab works in treating patients with progressive or relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01419795
- Testing
- lenalidomide, rituximab, pharmacological study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
This phase I/II trial studies the side effects and the best dose of veliparib when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with lymphoma, multiple myeloma…
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01326702
- Testing
- Bendamustine Hydrochloride, Pharmacological Study, Rituximab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Cataracts
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
The purpose of this study is to compare AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL in both eyes (bilateral implantation) to AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL in the dominant eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal…
- Trial name
- NCT01684007
- Testing
- AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1
- Volunteers
- 112 people
- Sponsor
- Alcon Research
Visual Acuity
Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL
The purpose of this study is to assess uniocular and binocular unaided distance, intermediate, and near VA; contrast sensitivity, accommodation amplitude, stereopsis, glare testing, ocular aberrations and the clinical…
- Trial name
- NCT00759096
- Testing
- RESTOR IOL Model SA60D3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alcon Research
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Delivery; Prolonged
Foley OR MisO for the Management of Induction
The percentage of women undergoing an induction of labor (IOL) is estimated to be 20% and continues to rise. Simultaneously, the cesarean delivery (CD) rate has continued to increase (2). Induction is a known risk factor for CD.
- Trial name
- FORMOMI (NCT01916681)
- Testing
- Cervical Foley & Misoprostol, Misoprostol Alone, Cervical Foley Alone
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- University of Pennsylvania
Cataract
ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)
Randomized, parallel group, subject masked, multi-center six (6) month follow-up study comparing ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power IOL Model SN6AD1 implanted in both eyes to ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power IOL…
- Trial name
- NCT00684138
- Testing
- ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens, ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Alcon Research
Presbyopia
Vivity IOL: Emmetropia Compared to Monovision.
Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities.
- Trial name
- NCT05464732
- Testing
- Vivity IOL emmetropia, Vivity IOL monovision
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Carolina Eyecare Physicians, LLC
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Ipilimumab and Local Radiation for Selected Solid Tumors
This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01769222
- Testing
- Ipilimumab, Radiation therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Cataract
Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)
The purpose of this study is to evaluate the safety and effectiveness of a new investigational modified light transmission monofocal intraocular lens compared to a conventional intraocular lens (IOL).
- Trial name
- NCT00747227
- Testing
- modified light transmission intraocular lens, monofocal acrylic intraocular lens
- Where
- 11 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Optics
Presbyopia, Pseudophakia
Synergy Lens Outcomes Evaluation
This is a single visit study to evaluate the visual outcomes and patient satisfaction of patients who were bilaterally implanted with the Tecnis Synergy IOL between June 1 and December 31, 2021 in 2 centers in USA
- Trial name
- NCT05418153
- Testing
- Tecnis Synergy IOL
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Center For Sight
Induced; Birth
Visual Aids for Induction of Labor RCT
This study aims to develop a visual aid tool for induction education informed by the experiences and needs of historically marginalized pregnant women, as well as determine the impact of the patient-informed visual aid on patient…
- Trial name
- VAIL (NCT05671224)
- Testing
- Visual aid
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT01805037
- Testing
- brentuximab vedotin, rituximab, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Cataracts
AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0] in Japan
The purpose of this study is to evaluate safety and effectiveness of AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0] in Japanese cataract patients.
- Trial name
- NCT01605877
- Testing
- AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]
- Where
- 2 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Alcon Research
Cataract, Presbyopia
Clinical Investigation of the Visual Outcomes and Safety of a Trifocal Intraocular Lens (IOL) in a Korean Population
The purpose of this study is to confirm the effectiveness of the investigational lens in a Korean population, especially for visual performance, quality of vision, and subject satisfaction with the visual outcome, as well as the…
- Trial name
- NCT03268746
- Testing
- AcrySof IQ PanOptix Multifocal IOL
- Where
- 4 sites in South Korea
- Volunteers
- 52 people
- Sponsor
- Alcon Research
Cataract
Surgeon Experience ReSTOR A +4 Intraocular Lens (IOL)
To collect visual outcome data post AcrySof ReSTOR Aspheric +4 implantation from surgeons throughout the United States.
- Trial name
- NCT00733512
- Testing
- ReSTOR
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Alcon Research
Cataract
Visual Outcomes After Cataract Surgery: Multifocal AcrySof® IQ ReSTOR® Intraocular Lenses Versus Monofocal Intraocular Lenses
The purpose of this study is to assess and compare visual outcomes of the AcrySof® IQ ReSTOR® +3.0 D intraocular lens (IOL) to a commercially available monofocal IOL in cataract patients.
- Trial name
- NCT01290068
- Testing
- AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, Monofocal IOL
- Volunteers
- 208 people
- Sponsor
- Alcon Research
Presbyopia
Clinical Performance of a Phakic Intraocular Lens (IOL)
This study will evaluate the clinical performance of a phakic intraocular lens (IOL) for the improvement of Uncorrected Near Visual Acuity (UCNVA) in subjects who require between +1.00 and +2.50 Reading Add.
- Trial name
- NCT03499821
- Testing
- EDOF ICL
- Where
- 6 sites in Belgium, Spain
- Volunteers
- 41 people
- Sponsor
- Staar Surgical Company
Aphakia, Presbyopia
Clareon PanOptix Pro vs. Clareon PanOptix - Study A
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
- Trial name
- NCT06400745
- Testing
- CPO Pro IOL, CPO IOL, Cataract surgery
- Where
- 8 sites in United States
- Volunteers
- 87 people
- Sponsor
- Alcon Research
Cataracts
Clinical Investigation of Visual Function After Bilateral Implantation of Two Presbyopia-Correcting Trifocal Intraocular Lenses (IOL)
The purpose of this study is to clinically evaluate the visual performance of two commercially available presbyopia-correcting Trifocal IOLs.
- Trial name
- NCT02691741
- Testing
- AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, AT LISA® tri IOL
- Volunteers
- 215 people
- Sponsor
- Alcon Research